Open AccessIMMUNOTHERAPY OF SOLID TOMOR BY INTRATUMORAL INFUSION OF LYMPHOKINE‐ACTIVATED KILLER CELLS
Author(s) -
Yamaki Toshiaki,
Ibayashi Yukihiro,
Nakamura Toru,
Shubo Noriharu,
Daibo Masahiko,
Kawahara Takahisa,
Hashi Kazuo
Publication year - 1988
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1988.tb00053.x
Subject(s) - lymphokine activated killer cell , lymphokine , spleen , cytotoxic t cell , gliosarcoma , immunotherapy , natural killer cell , cellular immunity , pathology , medicine , interleukin 2 , immunology , cell , cancer research , biology , immune system , t cell , interleukin 21 , in vitro , biochemistry , genetics , glioblastoma
Fifty million lymphokine‐activated killer (LAK) cells were infused into rat T9 gliosarcoma tumors for 1 hr at an infusion rate of 0.1 ml/hr. Cultured normal spleen cells were infused into similar tumors as a control. The LAK cell‐treated tumors began to regress at approximately 3 weeks after infusion and disappeared by 6 weeks, while the cultured normal spleen cell‐treated tumors grew progressively. Immunohistochemical analysis demonstrated prominent infiltration of cytotoxic/suppressor T cells in the LAK cell‐treated tumors, while few lymphocytes were recognized in the control tumors. These data suggested that LAK cells infused intratumorally might be capable of mediating tumor regression by inducing host immunity against the tumor.